Periodontal disease is a multifactorial inflammatory condition associated with bacterial dysbiosis and results in the progressive destruction of the supporting tissues of the teeth. It is one of the most common oral diseases worldwide. Despite advancements in treatment strategies, gingivitis is known to affect over 90% of the global population, making periodontal disease one of the most prevalent conditions and the sixth most common disease worldwide.
Amidst this burden, metformin, previously well known as an oral hypoglycemic agent, has emerged as a promising non-invasive therapeutic approach. The rationale behind its use lies in its ability to influence glucose metabolism pathways that also regulate inflammatory responses. In addition, metformin has been shown to promote stem cell proliferation and guide lineage commitment, both of which can contribute to tissue regeneration.
Importantly, when used locally in periodontal therapy, metformin may help harness these benefits while avoiding the systemic effects that could occur in non-diabetic individuals.
Although this approach is still under clinical investigation and has not yet been commercially marketed for this indication, the findings so far are noteworthy and highlight a potentially innovative direction in the management of periodontal disease.
4 Likes
An interesting and promising approach—repurposing a well-known drug like metformin for periodontal therapy highlights how innovation can come from existing treatments. It opens up new possibilities for more targeted and non-invasive management of periodontal disease.
I’d like to know if metformin is considered as a promising therapeutic approach , then why are a majority of diabetic patients suffering with periodontal infections and bone loss ? Is metformin effective only in those with no diabetes ?
is it used via local drug delivery mechanism or via oral route ??
Interesting example of drug repurposing in periodontal therapy.The regenerative and anti-inflammatory effects of metformin make this area worth further research.
1 Like
That’s definitely a very important question to raise in this context. From my perspective, the quantity of oral hypoglycemic agents that actually reaches the gums is not clinically effective, which is why a local, targeted therapy is required in these cases. This local therapy modulates both the inflammatory and regenerative aspects of periodontal healing. However, mechanical damage caused by poor oral hygiene also needs additional attention in the majority of patients, even those on an oral hypoglycemic agent
Currently, the local route of the drug dosage is under study, which includes a 1% concentration of metformin gel, which can typically be placed into the periodontal pockets.